SCHEMBL6883704

SCHEMBL6883704

O=C(Nc1ccc(O)c(C(=O)O)c1)OCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.64
ALDH1A1 P00352 2/20 0.64
KDM4E B2RXH2 2/20 0.64
MGLL Q99685 2/20 0.60
TP53 P04637 2/20 0.57
ATM Q13315 2/20 0.57
NPC1 O15118 1/20 0.57
TSHR P16473 1/20 0.57
RAB9A P51151 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
POLB P06746 2/20 0.56
ENPP2 Q13822 2/20 0.54
KDM4C Q9H3R0 1/20 0.53
ROCK2 O75116 1/20 0.53
EGFR P00533 1/20 0.53
MCL1 Q07820 1/20 0.51
KDM1A O60341 1/20 0.51
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
PTPN1 P18031 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7842397 0.89 MGLL (0.58) MAPTALDH1A1KDM4EMGLLTP53
SCHEMBL2293225 0.89 MGLL (0.60) MAPTALDH1A1MGLLTP53ATM
SCHEMBL7321919 0.88 EGFR (0.57) MAPTALDH1A1KDM4EMGLLTP53
SCHEMBL9147173 0.88 MAPT (0.53) MAPTALDH1A1KDM4EMGLLATM
SCHEMBL9149313 0.88 ALDH1A1 (0.53) MAPTALDH1A1KDM4EMGLLTP53
SCHEMBL8748204 0.88 MGLL (0.59) MAPTALDH1A1MGLLTP53ATM
SCHEMBL9149961 0.86 MGLL (0.62) MAPTALDH1A1KDM4EMGLLATM
SCHEMBL15388302 0.85 MGLL (0.59) MAPTALDH1A1MGLLTP53ATM
SCHEMBL12892589 0.83 MGLL (0.60) MAPTALDH1A1MGLLTP53ATM
SCHEMBL3175561 0.83 MGLL (0.60) MAPTALDH1A1MGLLTP53ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1211375-C Thiazole-derivaties HOFFMANN LA ROCHE (CH) 2005-07-20 CN disclosed
EP-1123283-B1 THIAZOLE-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-05-06 EP disclosed
EP-0928790-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2003-03-05 EP disclosed
CN-1359381-A Thiazole-derivaties HOFFMANN LA ROCHE (CH) 2002-07-17 CN disclosed
US-6358960-B1 FOR THERAPY OF INTRAVASCULAR COAGULATION, CORONARY THROMBOSIS, CEREBRAL INFARCTION, CEREBRAL EMBOLISM, TRANSIENT ISCHEMIC ATTACK, CEREBROVASCULAR DISORDERS, PULMONARY VASCULAR DISEASES, DEEP VENOUS THROMBOSIS, ETC. ONO PHARMACEUTICAL CO., LTD. (JP) 2002-03-19 US disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US disclosed
US-6297266-B1 INHIBIT THE BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES OF CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMANN-LA ROCHE INC. 2001-10-02 US disclosed
EP-1123283-A1 THIAZOLE-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-08-16 EP disclosed
US-5466655-A STORAGE STABILITY MITSUBISHI PAPER MILLS LIMITED (JP) 1995-11-14 US disclosed
EP-0675002-A1 Heat-sensitive recording material FUJI PHOTO FILM CO., LTD. (JP) 1995-10-04 EP disclosed
US-5424292-A 5-aminosalicylic acid derivatives for the therapy of chronic inflammatory bowel diseases DEPHA TEAM S.R.L. (IT) 1995-06-13 US disclosed
EP-0630758-A2 Heat-sensitive recording material MITSUBISHI PAPER MILLS, LTD. (JP) 1994-12-28 EP disclosed
EP-0548177-B1 5-AMINOSALICYLIC ACID DERIVATIVES FOR THE THERAPY OF CHRONIC INFLAMMATORY BOWEL DISEASES DEPHA TEAM SRL (IT) 1994-05-18 EP disclosed
US-5306688-A Color-forming, electron donating compound and electron accepting compound; storage stability of uncolored portion MITSUI TOATSU CHEMICALS, INC. (JP) 1994-04-26 US disclosed
EP-0548177-A1 5-AMINOSALICYLIC ACID DERIVATIVES FOR THE THERAPY OF CHRONIC INFLAMMATORY BOWEL DISEASES. DEPHA TEAM SRL (IT) 1993-06-30 EP disclosed
EP-0534257-A1 Salicylic acid derivatives, the process for preparing the same and the heat-sensitive recording materials comprising thereof MITSUI TOATSU CHEMICALS, Inc. (JP) 1993-03-31 EP disclosed
WO-1992004369-A1 5-AMINOSALICYLIC ACID DERIVATIVES FOR THE THERAPY OF CHRONIC INFLAMMATORY BOWEL DISEASES DEPHA TEAM S.R.L. (IT) 1992-03-19 WO disclosed
US-4146631-A ANTIALLERGENS, RESPIRATORY DISORDERS MAY & BAKER LIMITED (GB) 1979-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 MAPT 86/4885ALDH1A1 1400/4885KDM4E 4278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.